Skip to main content
. 2022 Jan 22;10(2):234. doi: 10.3390/biomedicines10020234

Figure 1.

Figure 1

The tyrosine metabolic pathway is inhibited in HCC. (A) Tyrosine metabolism pathway and related diseases. (B) The expression level of tyrosine-metabolizing enzymes in different tissues. (C) Statistics on the number of articles published by different keywords. (D) The types and frequency of mutations of tyrosine-metabolizing enzymes in HCC patients. (E,F) The tyrosine-metabolizing enzymes’ mRNA expression levels between tumor and normal tissues in patients with HCC in GEO database. The p values were determined by the two-tailed t-tests (* p < 0.05, ** p < 0.01, and *** p < 0.001).